AstraZeneca’s first-in-class FDA approval for Truqap marred by surprise restriction
Fierce Pharma
NOVEMBER 17, 2023
After the landmark success of Enhertu in HER2-low breast cancer, AstraZeneca has blazed another trail in the world’s most common cancer type. | After the landmark success of Enhertu in HER2-low breast cancer, AstraZeneca has blazed another trail in the world’s most common cancer type. But an unexpected restriction has cast a dark cloud over the first-in-class approval.
Let's personalize your content